ZELTIQ Aesthetics (ZLTQ) : Analyst Rating Update

ZELTIQ Aesthetics (ZLTQ) : The consensus on ZELTIQ Aesthetics (ZLTQ) based on 9 analyst recommendation on the company stock is 1.22, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

ZELTIQ Aesthetics (ZLTQ) : The most positive equity analysts on ZELTIQ Aesthetics (ZLTQ) expects the shares to touch $43, whereas, the least positive believes that the stock will trade at $32 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $38 with an expected fluctuation of $3.7 from the mean.

ZELTIQ Aesthetics (NASDAQ:ZLTQ): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $27.03 and $26.97 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $27.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $27.65, notching a gain of 1.47% for the day. The total traded volume was 375,443 . The stock had closed at $27.25 on the previous day.

Also, Brean Capital initiates coverage on ZELTIQ Aesthetics (NASDAQ:ZLTQ) The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency announces the price target to $35 per share. The rating by the firm was issued on April 13, 2016. The company shares have dropped -2.43% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $38.49 and the one year low was seen on Feb 16, 2016. The 50-Day Moving Average price is $27.43 and the 200 Day Moving Average price is recorded at $26.12.

ZELTIQ Aesthetics, Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists, plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells, which are needed to perform procedures using its CoolSculpting system. As of December 31, 2014, it had an installed base of 3,176 CoolSculpting systems installed across approximately 2,688 practices across the world. As of December 31, 2014, 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.